Tiziana Life Sciences Ltd
TLSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5 | $8 | $13 | $13 |
| G&A Expenses | $0 | $0 | $0 | $1 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $11 | $10 | $2 | $13 |
| Operating Expenses | $16 | $18 | $15 | $27 |
| Operating Income | -$16 | -$18 | -$15 | -$27 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | $1 | -$1 | $1 |
| Pre-Tax Income | -$17 | -$17 | -$15 | -$27 |
| Tax Expense | -$5 | $0 | $0 | -$3 |
| Net Income | -$12 | -$18 | -$15 | -$23 |
| % Margin | – | – | – | – |
| EPS | -0.22 | -0.34 | -0.3 | -0.48 |
| % Growth | 35.3% | -13.3% | 37.5% | – |
| EPS Diluted | -0.22 | -0.34 | -0.3 | -0.48 |
| Weighted Avg Shares Out | 53 | 51 | 51 | 49 |
| Weighted Avg Shares Out Dil | 53 | 51 | 51 | 49 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$17 | -$17 | -$15 | -$26 |
| % Margin | – | – | – | – |